Yun Fan

发表

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study

W. Mao, You-hua Jiang, Yun Fan, 2019, Cancer Chemotherapy and Pharmacology.

Hot button topic in the treatment of locally advanced esophageal carcinoma

Yun Fan, Yanjun Xu, 2018 .

PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.

Xiaoqing Yu, Fanrong Zhang, Kaiyan Chen, 2020, Lung cancer.

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.

Ying Cheng, Jian-hua Chang, Yunpeng Liu, 2020, The Lancet. Respiratory medicine.

糖皮质激素对免疫检查点抑制剂疗效影响的研究进展

Yun Fan, Guoqiang Pan, 2019, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706).

Chengping Hu, Gang Wu, Yong Fang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical and molecular characteristics of Chinese non‐small cell lung cancer patients with ERBB2 transmembrane domain mutations

S. Ou, Xue Wu, Y. Shao, 2020, Molecular oncology.

Camrelizumab Plus Apatinib in Extensive-Stage Small-Cell Lung Cancer (PASSION): A Multicenter, Two-Stage, Phase 2 Trial.

Lifeng Wang, Yong Fang, Haihua Yang, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.

Y. Shu, Caicun Zhou, Yun Fan, 2020, Lung Cancer.

A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer

W. Mao, Yun Fan, L. Fang, 2015, Cancer Chemotherapy and Pharmacology.

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.

Qi Li, P. Keegan, Jianxing He, 2022, Cancer cell.

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Ying Cheng, Wei Shi, Yunpeng Liu, 2022, The Lancet. Oncology.

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma

Y. Hu, Ying Cheng, Yi-long Wu, 2020, Frontiers in Oncology.

Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Cancer Immunology, Immunotherapy.

[Prospect and Current Situation of Immune Checkpoint Inhibitors  in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients].

Xiaoqing Yu, Yun Fan, Haiyang Wang, 2017, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

The transcription factor c-Jun regulates Smad4 expression by upregulating pre-miR-183 expression to promote invasion and metastasis of esophageal squamous cell carcinomas

W. Mao, Yun Fan, Xiaoling Xu, 2020, In Vitro Cellular & Developmental Biology - Animal.

PD-L1 and c-MET expression and survival in patients with small cell lung cancer

Yun Fan, Gu Zhang, Zhiyu Huang, 2017, Oncotarget.

Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients

Xiaoqing Yu, Kaiyan Chen, Yun Fan, 2017, Cancer Chemotherapy and Pharmacology.

Progress on treatment of MET signaling pathway in non-small cell lung cancer

Xiaoqing Yu, Yun Fan, Sizhe Yu, 2020, International Journal of Clinical Oncology.

c-MET通路和抑制剂在非小细胞肺癌中的研究进展

Xiaoqing Yu, Yun Fan, Yanjun Xu, 2017, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary

Xiaoqing Yu, Fanrong Zhang, Kaiyan Chen, 2022, Journal of translational medicine.

Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer

Xiaoqing Yu, You-hua Jiang, Yun Fan, 2018, OncoTargets and therapy.

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.

Jianxing He, Y. Shu, Yiping Zhang, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance

Yun Fan, Yanjun Xu, 2018, Cancer biology & therapy.

Retrospective analysis of hepatitis B virus reactivation after rituximab combination chemotherapy in patients with B-cell lymphoma

Yun Fan, Zhiyu Huang, Haifeng Yu, 2011 .

[Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].

Hai-feng Yu, Yun Fan, Zhiyu Huang, 2008, Ai zheng = Aizheng = Chinese journal of cancer.

Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases.

Xiaoqing Yu, Fanrong Zhang, Kaiyan Chen, 2018, Lung cancer.

Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.

Yun Fan, Zhiyu Huang, L. Gong, 2015, Lung cancer.

Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas

Hai-feng Yu, Yun Fan, L. Fang, 2011, Acta Pharmacologica Sinica.

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.

Ying Cheng, Yi-long Wu, B. Han, 2018, Translational lung cancer research.

Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer

Kaiyan Chen, Yun Fan, Zhiyu Huang, 2022, Thoracic cancer.

Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study

T. Mok, Yi-long Wu, Li Zhang, 2020, International journal of cancer.

The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study

Hui Li, Yun Fan, Xiaoling Xu, 2022, Cancers.

Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma

W. Mao, You-hua Jiang, Yun Fan, 2016, Oncotarget.

Real‐world utilization of EGFR TKIs and prognostic factors for survival in EGFR‐mutated non‐small cell lung cancer patients with brain metastases

Xiaoqing Yu, Yun Fan, Guoqiang Pan, 2021, International journal of cancer.

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

A. Drilon, M. Ahn, R. Doebele, 2022, JTO clinical and research reports.

Efficacy of bendamustine hydrochloride in patients with rituximab-refractory indolent B-cell non-Hodgkin's lymphoma: Results from a phase III multicenter study

Jun Zhu, X. Ke, Jifeng Feng, 2015 .

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations

He-long Zhang, N. Yang, Sanyuan Sun, 2022, JTO clinical and research reports.

A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors

Wei Chen, A. Rossi, R. Rosell, 2021, Translational lung cancer research.

Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial

Y. Shu, M. Dvorkin, Jie-Xie Wang, 2022 .

[Chinese Expert Consensus on Management of Special Adverse Effects  Associated with Lorlatinib].

Z. Hong, Yong Li, Zhe Liu, 2022, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Lorlatinib for Previously Treated ALK -Positive Advanced NSCLC: Primary Ef ﬁ cacy and Safety From a Phase 2 Study in People ’ s Republic of China

C. Bai, He-long Zhang, Jian-hua Chang, 2022 .

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.

Ying Cheng, He-long Zhang, N. Yang, 2021, The Lancet. Respiratory medicine.

Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer

J. Yi, Jianxing He, Jinjing Xia, 2022, Cancer medicine.

Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.

G. Curigliano, L. Paz-Ares, M. Schuler, 2021 .

Integrative and Comparative Genomic Analysis and the Immune Microenvironment Features of Lung Cancer Patients with Tuberculosis

W. Mao, C. Bao, Yun Fan, 2021 .

Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy

Tao Zhang, Wei Shi, Jian-hua Chang, 2022, Cancer communications.

Lung-molGPA Index Predicts Survival Outcomes of Non-Small-Cell Lung Cancer Patients with Synchronous or Metachronous Brain Metastases

Fanrong Zhang, Kaiyan Chen, Yun Fan, 2020, OncoTargets and therapy.

1p/19q codeletion and RET rearrangements in small-cell lung cancer

W. Mao, Yun Fan, J. Qin, 2016, OncoTargets and therapy.

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Ying Cheng, P. Keegan, Baolan Li, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRAF突变晚期NSCLC的靶向和免疫治疗研究进展

Yun Fan, Yanjun Xu, Na Li, 2021, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Real‐world treatment and prognostic factors for survival in ALK+ non‐small cell lung cancer (NSCLC) patients with brain metastases in China

Xiaoqing Yu, Yun Fan, Jiamin Sheng, 2022, Thoracic cancer.

A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib.

Xiaoqing Yu, Fanrong Zhang, Kaiyan Chen, 2020, Clinical lung cancer.

Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12).

Baolan Li, Chengping Hu, P. Sun, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

W. Wei, K. Nan, Jun Liang, 2016, Chinese clinical oncology.

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

W. Wei, K. Nan, Jun Liang, 2015, Annals of translational medicine.

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup

Yun Fan, Xiaoling Xu, M. Xie, 2021, Frontiers in Oncology.

Human liver microsomal metabolism of (+)-discodermolide.

B. Day, Yun Fan, Emanuel M. Schreiber, 2009, Journal of natural products.

THE IN VITRO METABOLISM OF THREE ANTICANCER DRUGS

Yun Fan, 2007 .

Dual-negative expression of Nrf2 and NQO1 predicts superior outcomes in patients with non-small cell lung cancer

N. Lin, D. Su, Yun Fan, 2017, Oncotarget.

Clinical Relevance of PD-L1 Expression and CD8+ T Cells’ Infiltration in Patients With Lung Invasive Mucinous Adenocarcinoma

Wei Chen, Ding Wang, Yun Fan, 2021, Frontiers in Oncology.

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

G. Curigliano, L. Paz-Ares, M. Schuler, 2022, Nature Medicine.

Towards customized cancer vaccines: a promising filed in personalized cancer medicine

Yun Fan, Xiaoling Xu, Hui Li, 2021, Expert review of vaccines.

Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.

P. Jänne, Ying Cheng, C. Chiu, 2021 .

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions

Fanrong Zhang, Kaiyan Chen, Yun Fan, 2020, Thoracic cancer.

Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy

Xiaoqing Yu, Kaiyan Chen, Yun Fan, 2020, Translational lung cancer research.

Immune checkpoint inhibitors in lung cancer: current status and future directions.

W. Mao, Yun Fan, 2017, Chinese clinical oncology.

Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma

Xue Wu, Y. Shao, J. Qin, 2018, BMC Cancer.

Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges.

Yun Fan, Ye Yang, Hui Li, 2023, Cancer treatment reviews.

Short-Term Responders of Non–Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms

Xue Wu, Y. Shao, Yun Fan, 2018, Translational oncology.

Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer

Xuehua Zhu, W. Mao, Yun Fan, 2017, Clinical Cancer Research.

Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First‐Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung — A Multicenter, Open‐label, Randomized, Phase III Trial

Chengping Hu, Gang Wu, Shun Lu, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation

Yun Fan, Shifeng Yang, Xin-min Yu, 2018, Journal of Cancer.

Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China

Xiaoqing Yu, Kaiyan Chen, Yun Fan, 2021, Thoracic cancer.

Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma

Jianxing He, Guangfa Wang, Junling Li, 2021, Theranostics.

Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study

Wenfeng Li, Ming Chen, Jun Zhao, 2019, British Journal of Cancer.

Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells.

B. Day, Yun Fan, J. Yalowich, 2006, Chemical research in toxicology.

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer

Y. Shao, Jun Zhao, Ying-yu Jin, 2020, Frontiers in Oncology.

Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial.

Ying Cheng, Y. Shu, M. Dvorkin, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer.

Ying Cheng, He-long Zhang, Yunpeng Liu, 2019, Oncology letters.

The efficacy and safety of anti‐PD‐1/PD‐L1 antibodies combined with chemotherapy or CTLA4 antibody as a first‐line treatment for advanced lung cancer

Yun Fan, Xiaoling Xu, Zhiyu Huang, 2018, International journal of cancer.

Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study

J Zhang, Jianxing He, Guangfa Wang, 2021, Cancer communications.

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer

Ying Cheng, H. Wakelee, T. Mok, 2021, JAMA oncology.

Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.

A. Dechaphunkul, J. Maneechavakajorn, Chia‐Chi Lin, 2020, European journal of cancer.

Real-World Data on Prognostic Factors for Overall Survival in EGFR-Mutant Non-Small-Cell Lung Cancer Patients with Brain Metastases

Xiaoqing Yu, Yun Fan, 2019, Journal of Cancer.

Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis

Yun Fan, Yunyun Lu, 2016, OncoTargets and therapy.

A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity

Yun Fan, Zhiyu Huang, L. Gong, 2017, Anti-cancer drugs.

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804)

Ying Cheng, B. Han, Yunpeng Liu, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR敏感突变NSCLC患者的最佳治疗模式探讨

Yun Fan, Zhong-Qiao Shi, Yunping Fan, 2015, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data

C. Xie, Yun Fan, Xiaoling Xu, 2014, OncoTargets and therapy.

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial

J Zhang, Jianxing He, N. Ma, 2021, Signal Transduction and Targeted Therapy.

Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases

Yun Fan, J. Qin, Hongyang Lu, 2017, Scientific Reports.

Ef ﬁ cacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study

He-long Zhang, Baolan Li, Yu-Mei Shi, 2022 .

Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell lung cancer.

Y. Liu, Jingjing Liu, Xian-hong Liu, 2016, Future oncology.

Current small cell lung cancer treatment in China

B. Han, Chengping Hu, P. Xing, 2015, Thoracic cancer.

MA11.06 A PII Study of Toripalimab, a PD-1 mAb, in Combination with Chemotherapy in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies

J Zhang, N. Ma, R. Guo, 2019, Journal of Thoracic Oncology.

Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma

Xia Li, You-hua Jiang, Yue Zhao, 2020, Journal of Cancer.

The Novel Tumor Microenvironment-Related Prognostic Gene AIF1 May Influence Immune Infiltrates and is Correlated with TIGIT in Esophageal Cancer

Ding Wang, Yun Fan, Xiaoling Xu, 2021, Annals of Surgical Oncology.

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial

Li Zhou, Yun Fan, X. Bai, 2021, Frontiers in Oncology.

Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer

Yun Fan, Yanjun Xu, Hui Li, 2021, Frontiers in Oncology.

Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study

K. Gu, Yun Fan, Jian Zhang, 2012, Cancer Chemotherapy and Pharmacology.

Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses—reply

Ming Chen, Xiao-ling Xu, You-hua Jiang, 2019, Cancer.

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

Ying Cheng, Yi-long Wu, B. Han, 2017, ESMO Open.

Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer

Yongchang Zhang, Yun Fan, Zhiyu Huang, 2022, Cell death & disease.

1p/19q codeletion and RET rearrangements in small-cell lung cancer

W. Mao, Yun Fan, J. Qin, 2016, OncoTargets and therapy.

Decoding the Evolutionary Response to Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA Sequencing.

W. Feng, Xiaoqing Liu, Yunpeng Liu, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer

Xiaoqing Yu, Kaiyan Chen, Yun Fan, 2021, Translational cancer research.

Lorlatinib for Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer: Primary Efficacy and Safety From a Phase 2 Study in China.

Ying Cheng, C. Bai, He-long Zhang, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.

W. Feng, Xiaoqing Liu, Yunpeng Liu, 2019, The Lancet. Respiratory medicine.

Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases

Kaiyan Chen, Yun Fan, Zhiyu Huang, 2021, Molecular brain.

Keap1–Nrf2 pathway: A promising target towards lung cancer prevention and therapeutics

Yun Fan, Bo Zhang, Y. Tong, 2015, Chronic diseases and translational medicine.

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.

T. Wang, D. Zhong, Yanqiu Zhao, 2023, Lung cancer.

Ef ﬁ cacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/ Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study

T. Wang, D. Zhong, Yanqiu Zhao, 2022 .

Expert consensus on treatment for stage III non‐small cell lung cancer

W. Liang, Jin-Ji Yang, Long Chen, 2023, Medicine Advances.

ASO Author Reflection: The TME-Related Gene AIF1 Signature Predicts Esophageal Carcinoma Prognosis

Yun Fan, Xiaoling Xu, Ding Wang, 2022, Annals of Surgical Oncology.

Anticancer drug R&D landscape in China

Bing-he Xu, Y. Ba, L. Shen, 2020, Journal of Hematology & Oncology.

Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase III study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations

Ying Cheng, Baolan Li, Xiao-Li Zhu, 2022, Journal of Clinical Oncology.

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study

Ying Cheng, Yulan Sun, Sanyuan Sun, 2022, Therapeutic advances in medical oncology.

NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.

N. Shire, Jian-hua Chang, Si Sun, 2023, Lung cancer.

The efficacy and safety of anti-PD-1 / PD-L 1 antibodies combined with chemotherapy or CTLA 4 antibody as a first-line treatment for advanced lung cancer

Yun Fan, Xiaoling Xu, Zhiyu Huang, 2022 .

Abstract CT038: Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial

Baolan Li, Huiqing Yu, Chengping Hu, 2022, Cancer Research.

Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.

Ying Cheng, C. Chiu, P. Janne, 2022, Journal of Clinical Oncology.

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Ying Cheng, C. Chiu, P. Janne, 2022, Cancer discovery.

[Phase II trial of improved regimen with gemcitabine in patients with advanced non-small cell lung cancer].

Yun Fan, Zhiyu Huang, Haifeng Yu, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer

S. Chuai, Xiaojie Pan, S. Cai, 2023, EBioMedicine.

Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12

Sijie Feng, Yun Fan, Hui Li, 2023, Frontiers in Immunology.

Abstract CT039: Results from RATIONALE 303: A global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic NSCLC

Ying Cheng, Yunpeng Liu, Y. Shu, 2021, Clinical Trials.

Bevacizumab treatment for advanced non-small cell lung cancer: A case report

W. Mao, Yun Fan, Zhiyu Huang, 2013, Oncology letters.

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study

Ying Cheng, Yulan Sun, Sanyuan Sun, 2022, Therapeutic advances in medical oncology.

Extensive‐stage small‐cell lung cancer: Current management and future directions

Kaiyan Chen, Yun Fan, Ying Yu, 2022, International journal of cancer.

JAK2 variations and functions in lung adenocarcinoma

Juan Jin, Jiawei Xu, Yun Fan, 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.

Jianxing He, Y. Shu, Yiping Zhang, 2019, Journal of Clinical Oncology.

Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer

Yamei Chen, C. Gay, Yuhua Gong, 2021, Clinical Cancer Research.

Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboringMET exon 14skipping alterations (METex14)

Ying Cheng, Yulan Sun, Sanyuan Sun, 2021, Clinical Trials.

Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status

Xiaoqing Yu, Yun Fan, 2019, Medicine.

Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients

W. Mao, Yun Fan, L. Fang, 2013, OncoTargets and therapy.

Safety and efficacy of atezolizumab in Chinese patients with previously treated locally advanced or metastatic non-small cell lung cancer: An open-label, single-arm, multicenter study.

Jian-hua Chang, Si Sun, Juan Li, 2023, Lung cancer.

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations

Wenfeng Li, Baocheng Wang, J. Wang, 2023, Therapeutic advances in medical oncology.

Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study.

Q. Liu, Caicun Zhou, Yun Fan, 2023, European journal of cancer.

Tumor Microenvironment-Associated Immune-Related Genes for the Prognosis of Malignant Pleural Mesothelioma

W. Mao, Yun Fan, Xiaoling Xu, 2020, Frontiers in Oncology.

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.

X. Chen, Pengxiang Wu, R. Guo, 2023, The Lancet. Respiratory medicine.

Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)

W. Liang, Chuanhao Tang, Jin-liang Wang, 2023, Journal of the National Cancer Center.

Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.

Jie Yang, Gregory Riely, F. de Marinis, 2023, Journal of Clinical Oncology.

Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results.

Ying Cheng, Yanqiu Zhao, Yong He, 2023, Journal of Clinical Oncology.

Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?

Yun Fan, Xiaoling Xu, Ning Chen, 2023, Therapeutic advances in medical oncology.

Safety but Limited Efficacy of Ensartinib in ROS1-Positive Non-small Cell Lung Cancer: A Single-arm, Multicenter Phase II study.

Ying Cheng, He-long Zhang, Cheng Huang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

小细胞肺癌维持治疗的研究进展

Yun Fan, Yunyun Lu, 云云 Yunyun 陆 LU, 2015, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Short-Term Responders of Non – Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP 53 Mutations and Primary Resistance Mechanisms 1 , 2

Xue Wu, Y. Shao, Yun Fan, 2018 .

Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

Hui Li, Kaiyan Chen, Yun Fan, 2023, Cancer medicine.

Efficacy and safety of pralsetinib in patients with advanced RET fusion‐positive non–small cell lung cancer

Jian-hua Chang, Ke Wang, Jun Zhao, 2023, Cancer.

A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis.

J Zhang, Jianxing He, N. Ma, 2020 .

A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).

N. Yang, Yu-xiang Ma, Yun Fan, 2023, Lung cancer.